D-0791-2023 Class II Ongoing
FDA drug recall D-0791-2023 was initiated by Akorn, Inc. on Apr 26, 2023 and is designated Class II. Reason for recall: CGMP Deviations: Firm went out of business and could no longer continue stability studies. The recall status is ongoing.
Recall details
- Product Type
- Drugs
- Report Date
- Jun 7, 2023
- Initiation Date
- Apr 26, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
Product description
Cetrorelix Acetate for Injection, 0.25 mg, , One carton contains one packaged tray which contains: 1 vial with lyophilized powder for reconstitution, 1 pre-filled syringe with diluent, 1 20-gauge needle, 1 27-gauge needle, Sterile - For subcutaneous use only, Rx Only, Manufactured by: GP Pharm S.A. Barcelona, Spain (ESP) -08777, Distributed by: Akorn Operating Company, LLC., Gurnee, IL 60031. ALL NDCs
Reason for recall
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
Distribution pattern
Nationwide in the USA and Puerto Rico
Code information
All Lots
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0791-2023
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026